Several other analysts have also weighed in on the stock. Piper Jaffray Companies boosted their target price on shares of Apyx Medical to $10.00 and gave the company an overweight rating in a research note on Monday, November 11th. Zacks Investment Research downgraded shares of Apyx Medical from a buy rating to a hold rating in a research report on Tuesday. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $8.94.
NASDAQ:APYX traded up $0.06 during mid-day trading on Wednesday, reaching $8.37. The stock had a trading volume of 1,981 shares, compared to its average volume of 76,445. The company has a market capitalization of $274.20 million, a price-to-earnings ratio of -28.76 and a beta of 0.15. Apyx Medical has a 1-year low of $3.55 and a 1-year high of $8.89. The stock’s 50 day simple moving average is $8.03 and its two-hundred day simple moving average is $7.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.73 and a quick ratio of 7.93.
Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Monday, November 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $7.58 million for the quarter, compared to analysts’ expectations of $6.78 million. Apyx Medical had a negative return on equity of 20.25% and a negative net margin of 66.77%. The company’s revenue was up 106.3% compared to the same quarter last year. Sell-side analysts anticipate that Apyx Medical will post -0.6 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in APYX. Bank of Montreal Can grew its stake in Apyx Medical by 277.9% during the 2nd quarter. Bank of Montreal Can now owns 3,779 shares of the company’s stock worth $26,000 after buying an additional 2,779 shares during the last quarter. Astoria Strategic Wealth Inc. bought a new position in Apyx Medical in the 4th quarter worth approximately $86,000. Metropolitan Life Insurance Co NY acquired a new stake in Apyx Medical in the 3rd quarter valued at approximately $87,000. Frisch Financial Group Inc. increased its position in Apyx Medical by 31.7% in the 3rd quarter. Frisch Financial Group Inc. now owns 17,658 shares of the company’s stock valued at $120,000 after acquiring an additional 4,248 shares during the period. Finally, Rhumbline Advisers raised its stake in Apyx Medical by 21.6% during the 3rd quarter. Rhumbline Advisers now owns 37,346 shares of the company’s stock valued at $253,000 after acquiring an additional 6,634 shares in the last quarter. Institutional investors and hedge funds own 51.99% of the company’s stock.
Apyx Medical Company Profile
Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue.
Read More: What is the definition of arbitrage?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.